This company has been acquired
Mersana Therapeutics (MRSN) Aktievy
Mersana Therapeutics, Inc. är ett biofarmaceutiskt företag i klinisk fas som utvecklar antikropps-läkemedelskonjugat (ADC) för cancerpatienter med icke tillgodosedda behov. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 1/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
MRSN Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mersana Therapeutics, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$29.08 |
| 52 veckors högsta | US$35.23 |
| 52 veckors lägsta | US$5.21 |
| Beta | 0.43 |
| 1 månads förändring | 4.15% |
| 3 månaders förändring | 220.62% |
| 1 års förändring | -10.52% |
| 3 års förändring | -79.98% |
| 5 års förändring | -93.92% |
| Förändring sedan börsintroduktionen | -91.69% |
Senaste nyheter och uppdateringar
MRSN: Cash Offer And CVR Potential Will Drive Future Deal Upside
Analysts trimmed their price targets on Mersana Therapeutics toward the US$25 cash takeout level, with some assigning additional value to the up to US$30.25 per share in contingent value rights tied to the proposed acquisition by Day One Biopharmaceuticals, and we adjusted our assumptions slightly to reflect this revised risk and return profile. Analyst Commentary Recent Street research on Mersana Therapeutics has largely converged around the announced acquisition terms, with most firms shifting to more neutral ratings as the stock price is seen as anchored to the US$25 cash offer plus the potential contingent value right payouts.MRSN: Cash Buyout And CVR Structure Will Drive Future Shareholder Upside
Mersana Therapeutics' analyst price target is effectively unchanged at $33.20 per share, as analysts largely anchor their valuation to the agreed $25.00 per share cash acquisition price plus the potential value of up to $30.25 per share in contingent payments, while assigning a probability discount to the CVR milestones. Analyst Commentary Analyst sentiment has shifted to a more neutral stance following the announced acquisition, with most firms moving to hold or market perform ratings and framing upside or downside almost entirely through the lens of deal completion and CVR realization rather than standalone fundamentals.MRSN: Acquisition Will Drive Shareholder Value With Up To $30.25 Milestone Upside
The analyst price target for Mersana Therapeutics has been lowered following news of its acquisition by Day One Biopharmaceuticals. Analysts cited the deal terms and reduced likelihood of competitive bidding as the rationale for the updated valuation.Recent updates
MRSN: Cash Offer And CVR Potential Will Drive Future Deal Upside
Analysts trimmed their price targets on Mersana Therapeutics toward the US$25 cash takeout level, with some assigning additional value to the up to US$30.25 per share in contingent value rights tied to the proposed acquisition by Day One Biopharmaceuticals, and we adjusted our assumptions slightly to reflect this revised risk and return profile. Analyst Commentary Recent Street research on Mersana Therapeutics has largely converged around the announced acquisition terms, with most firms shifting to more neutral ratings as the stock price is seen as anchored to the US$25 cash offer plus the potential contingent value right payouts.MRSN: Cash Buyout And CVR Structure Will Drive Future Shareholder Upside
Mersana Therapeutics' analyst price target is effectively unchanged at $33.20 per share, as analysts largely anchor their valuation to the agreed $25.00 per share cash acquisition price plus the potential value of up to $30.25 per share in contingent payments, while assigning a probability discount to the CVR milestones. Analyst Commentary Analyst sentiment has shifted to a more neutral stance following the announced acquisition, with most firms moving to hold or market perform ratings and framing upside or downside almost entirely through the lens of deal completion and CVR realization rather than standalone fundamentals.MRSN: Acquisition Will Drive Shareholder Value With Up To $30.25 Milestone Upside
The analyst price target for Mersana Therapeutics has been lowered following news of its acquisition by Day One Biopharmaceuticals. Analysts cited the deal terms and reduced likelihood of competitive bidding as the rationale for the updated valuation.MRSN: Acquisition Offer And Milestone Payments Will Drive Substantial Shareholder Upside
The analyst price target for Mersana Therapeutics was raised from $28.29 to $33.20 per share, as analysts cite the premium acquisition offer by Day One Biopharmaceuticals as well as anticipated improvements in profit margin and revenue growth as driving factors. Analyst Commentary Following the acquisition announcement, analysts have revised their perspectives on Mersana Therapeutics, weighing the strategic rationale behind the deal and its implications for shareholder value and future growth.Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Oct 11
ADC Trials Will Reshape Personalized Cancer Treatments
Analysts maintained their $28.29 price target for Mersana Therapeutics following a reverse stock split and updated Q2 2025 financials, with continued optimism regarding Emi-Le’s clinical progress and long-term prospects. Analyst Commentary Price target reductions primarily reflect adjustments for the 1-for-25 reverse stock split rather than changes in fundamental outlook.Rainbows and Unicorns: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Just Became A Lot More Optimistic
Aug 15Revenues Working Against Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Share Price Following 25% Dive
Aug 09Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Jun 11
Emi-Le Trials And TNBC Focus Will Deliver Promise With Risk
Emi-Le's promising clinical trial results and focus on unmet needs in breast cancer could drive significant future revenue and market share gains.Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Mar 27Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts
Mar 08Mersana Therapeutics, Inc. (NASDAQ:MRSN) Not Doing Enough For Some Investors As Its Shares Slump 69%
Jan 15Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable
Dec 19Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Dec 01Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly?
Nov 08Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 03Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade
Aug 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%
Aug 13Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues
Jun 19Mersana Therapeutics: On Hold While Waiting For Any Positive News
May 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%
Apr 25Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry
Feb 27Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock
Jan 11Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money
Oct 14Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Jun 09Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price
Feb 22Mersana gains as FDA grants fast track status for breast cancer drug
Sep 12Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
Aug 15Aktieägarnas avkastning
| MRSN | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 0.5% | -2.4% | 0.8% |
| 1Y | -10.5% | 27.4% | 27.8% |
Avkastning vs industri: MRSN presterade sämre än US Biotechs branschen som gav 27.4 % under det senaste året.
Avkastning vs Marknaden: MRSN presterade sämre än US marknaden som gav 27.8 % under det senaste året.
Prisvolatilitet
| MRSN volatility | |
|---|---|
| MRSN Average Weekly Movement | 60.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: MRSN s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: MRSN s veckovolatilitet har ökat från 33% till 61% under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2001 | 102 | Marty Huber | www.mersana.com |
Mersana Therapeutics, Inc. är ett biofarmaceutiskt företag i klinisk fas som utvecklar antikropps-läkemedelskonjugat (ADC) för cancerpatienter med ouppfyllda behov. Bolaget utvecklar Emi-Le (XMT-1660), en B7-H4-riktad Dolasynthen ADC-kandidat, som befinner sig i klinisk fas 1-studie, och XMT-2056, en Immunosynthen ADC riktad mot en ny human epidermal tillväxtfaktorreceptor 2, som befinner sig i klinisk fas 1-studie. Bolagets prekliniska produktportfölj omfattar XMT-2068 och XMT-2175.
Mersana Therapeutics, Inc. Sammanfattning av grunderna
| MRSN grundläggande statistik | |
|---|---|
| Börsvärde | US$145.39m |
| Vinst(TTM) | -US$70.08m |
| Intäkter(TTM) | US$33.18m |
Är MRSN övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| MRSN resultaträkning (TTM) | |
|---|---|
| Intäkter | US$33.18m |
| Kostnad för intäkter | US$69.03m |
| Bruttovinst | -US$35.85m |
| Övriga kostnader | US$34.23m |
| Intäkter | -US$70.08m |
Senast redovisade vinst
Sep 30, 2025
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -14.02 |
| Bruttomarginal | -108.04% |
| Nettovinstmarginal | -211.21% |
| Skuld/egenkapitalförhållande | 0% |
Hur har MRSN utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/01/07 01:14 |
| Aktiekurs vid dagens slut | 2026/01/05 00:00 |
| Intäkter | 2025/09/30 |
| Årlig intjäning | 2024/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Mersana Therapeutics, Inc. bevakas av 3 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Konstantinos Aprilakis | Stifel, Equities Research |
| Tara Bancroft | TD Cowen |